UTAH MEDICAL PRODUCTS INC(UTMD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,164 of 2,879 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
UTMD Stock Analysis & AI Quality Score
AI stock analysis and institutional research for UTAH MEDICAL PRODUCTS INC (UTMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores UTMD at 55.4/100 on a 32-signal composite quality model, placing it at rank #1,164 of 2,879 stocks — the top half of the AI-ranked universe. UTMD scores in the top quartile across free cash flow (88.8), profitability (87.6), institutional flow (85.4). Areas of concern include revenue scale (8.9) and revenue growth (11.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), UTAH MEDICAL PRODUCTS INC reports quarterly revenue of $8.7M, net income of $2.6M, an operating margin of 29.4%. Top institutional holders of UTMD by reported 13-F value include BRANDES INVESTMENT PARTNERS,, DIMENSIONAL FUND ADVISORS, BlackRock,, based on the most recent SEC filings. UTMD trades on the Nasdaq exchange and files with the SEC under CIK 706698. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate UTMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for UTAH MEDICAL PRODUCTS INC directly from SEC EDGAR. UTAH MEDICAL PRODUCTS INC's 13F Pro composite quality score has ranged between 54 and 65 since 2021, currently 55.4 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.
Revenue
Q1 2026
$8.7M
Net Income
Q1 2026
$2.6M
Free Cash Flow
Q1 2026
$3.0M
Operating Margin
Q1 2026
29.4%
D/E Ratio
Q1 2026
0.00
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-18.6% YoYOperating Income
-19.0% YoYEPS (Diluted)
-13.3% YoYTotal Assets
-9.5% YoYTotal Debt
-4.4% YoYOp. Cash Flow
-33.4% YoY| Metric | FY 2024 | FY 2023 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $40.9M -18.6% | $50.2M +7.1% | $46.9M +11.7% | $42.0M +1.4% | $41.4M +5.4% | $39.3M |
| Operating Income | $13.6M -19.0% | $16.8M -4.8% | $17.6M -5.7% | $18.7M -1.7% | $19.0M +17.4% | $16.2M |
| EPS (Diluted) | $3.96 -13.3% | $4.57 +16.0% | $3.94 -20.4% | $4.95 +117.5% | $2.28 -29.2% | $3.21 |
| Total Assets | $122.5M -9.5% | $135.5M +23.4% | $109.8M +10.0% | $99.8M +7.6% | $92.7M +21.7% | $76.2M |
| Total Debt | $282.0K -4.4% | $295.0K | $0.00 | $0.00 | $0.00 | — |
| Operating Cash Flow | $14.8M -33.4% | $22.3M +30.6% | $17.1M +1.3% | $16.8M -0.4% | $16.9M +16.4% | $14.5M |
AI Insight: UTMD Financial Trends
Revenue flat at $9–10M quarterly with operating income stable at $2–3M; minimal leverage but no growth momentum.
• Revenue ranged $9–10M across all 8 quarters with no discernible growth trajectory; Q4 2025 and Q1 2026 both $9M.
• Operating income held steady at $2–3M per quarter; Q4 2025 dipped to $2M, recovered to $3M in Q1 2026.
• Operating cash flow oscillated $3–4M quarterly; no sustained improvement or deterioration over the period.
• Zero debt maintained throughout; equity edged up from $117M (Q4 2024) to $120M (Q1 2026).
⚠ Operating income weakness in Q4 2025 ($2M vs. historical $3M) — first decline in two quarters; monitor Q2 2026.
⚠ Stagnant revenue over 8 quarters signals lack of top-line growth; competitive or market headwinds unclear from financials.
AI Insight: UTMD Ratio Trends
Operating margin rebounded to 29.4% in Q1 2026, but ROIC remains structurally depressed—down 190 bps from peak Q2 2024.
• Operating margin fell from 33.1% (Q2 2024) to 26.6% (Q3 2025), recovering partially to 29.4% in Q1 2026.
• ROIC declined from 11.1% (Q2 2024) to 8.5% (Q1 2026), a sustained 260 bp deterioration over 18 months.
• D/E ratio remains zero or immaterial across all periods; balance sheet leverage unchanged.
⚠ Q3 2025 marked a sharp margin trough (26.6%); sustained recovery above 30% needed to confirm trend reversal.
⚠ ROIC persistently below 9% since Q3 2025; capital efficiency has not recovered despite margin rebound.
Get alerted when UTMD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for UTAH MEDICAL PRODUCTS INC including:
Top Institutional Holders of UTMD
BRANDES INVESTMENT PARTNERS, LP
$27.9M449,279 shDIMENSIONAL FUND ADVISORS LP
$12.3M197,908 shBlackRock, Inc.
$11.6M187,649 shRENAISSANCE TECHNOLOGIES LLC
$11.4M184,114 shVANGUARD CAPITAL MANAGEMENT LLC
$8.6M138,560 shGEODE CAPITAL MANAGEMENT, LLC
$7.4M120,097 shMinerva Advisors LLC
$5.8M93,615 shHOTCHKIS & WILEY CAPITAL MANAGEMENT LLC
$5.5M89,131 shRICE HALL JAMES & ASSOCIATES, LLC
$4.2M67,882 shSTATE STREET CORP
$4.0M64,402 sh
| Fund | Value | Shares |
|---|---|---|
| BRANDES INVESTMENT PARTNERS, LP | $27.9M | 449,279 |
| DIMENSIONAL FUND ADVISORS LP | $12.3M | 197,908 |
| BlackRock, Inc. | $11.6M | 187,649 |
| RENAISSANCE TECHNOLOGIES LLC | $11.4M | 184,114 |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.6M | 138,560 |
| GEODE CAPITAL MANAGEMENT, LLC | $7.4M | 120,097 |
| Minerva Advisors LLC | $5.8M | 93,615 |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | $5.5M | 89,131 |
| RICE HALL JAMES & ASSOCIATES, LLC | $4.2M | 67,882 |
| STATE STREET CORP | $4.0M | 64,402 |
More Healthcare Companies
View all Healthcare →Put UTMD on your watchlist
Track score changes the day UTAH MEDICAL PRODUCTS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is UTMD a good stock to buy?
13F Pro's AI-powered analysis of UTAH MEDICAL PRODUCTS INC (UTMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for UTMD are available on the UTMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own UTMD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling UTMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of UTAH MEDICAL PRODUCTS INC's investment landscape.